Consensus Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.04 ^USD	+5.70%		-1.45%	-38.74%

Apr. 24	Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	CI
Mar. 20	HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	MT

Evolution of the average Target Price on Coherus BioSciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

60e91.pBOQZ9PZtwfCYybWrGYv8zod8TLK1Co6h-WcVxy6THA.8CLEE5G21Em0MUqAnAFl3lluq0GOv2tcyrfKG3TCfTLeRNc0hbXlT48OZw~024e3fb3a532a282741d40f3ab9c6458

Analyst Recommendations on Coherus BioSciences, Inc.

HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	Mar. 20	MT
Baird Cuts Coherus BioSciences' Price Target to $9 From $11, Outperform Rating Maintained	Jan. 23	MT
Truist Securities Cuts Coherus BioSciences' Price Target to $8 From $12, Maintains Buy Rating	Jan. 23	MT
Swiss Equities Rally as Rate Decisions, Economic Data Take Center Stage	Jan. 22	MT
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	Dec. 27	DJ
Baird Initiates Coherus BioSciences With Outperform Rating, $11 Price Target	Nov. 17	MT
Maxim Downgrades Coherus BioSciences to Hold From Buy	Nov. 08	MT
HC Wainwright Cuts Price Target on Coherus BioSciences to $13 From $20, Maintains Buy Rating	Nov. 07	MT
Central bank bonanza!	23-10-30
North American Morning Briefing : Rate Decisions, Jobs Data Headline a Busy Week	23-10-30	DJ
Futures jump as investors await Fed rate verdict; Middle East tensions eyed	23-10-30	RE
Barclays Adjusts Coherus BioSciences' Price Target to $7 From $8, Maintains Overweight Rating	23-10-23	MT
UBS Adjusts Coherus BioSciences Price Target to $7 From $11, Maintains Buy Rating	23-08-07	MT
HC Wainwright Adjusts Price Target on Coherus BioSciences to $20 From $24, Maintains Buy Rating	23-08-03	MT
Citigroup Initiates Coherus BioSciences at Buy Rating With $12 Price Target	23-07-24	MT
Truist Securities Trims Price Target on Coherus BioSciences to $20 From $22, Maintains Buy Rating	23-07-14	MT
Truist Securities Trims Price Target on Coherus BioSciences to $22 From $24, Maintains Buy Rating	23-06-20	MT
Barclays Adjusts Coherus BioSciences' Price Target to $8 From $13, Keeps Overweight Rating	23-05-23	MT
HC Wainwright Adjusts Price Target on Coherus BioSciences to $24 From $26, Keeps Buy Rating	23-05-09	MT
Truist Starts Coherus BioSciences at Buy With $24 Price Target	23-05-01	MT
UBS Upgrades Coherus BioSciences to Buy From Neutral, $11 Price Target	23-03-28	MT
Barclays Adjusts Price Target on Coherus BioSciences to $13 From $15, Maintains Overweight Rating	23-03-08	MT
HC Wainwright Adjusts Coherus BioSciences Price Target to $26 From $30, Maintains Buy Rating	23-03-07	MT
Mizuho Trims Price Target on Coherus BioSciences to $21 From $28, Maintains Buy Rating	22-11-15	MT
JPMorgan Adjusts Price Target on Coherus BioSciences to $11 From $13, Maintains Neutral Rating	22-11-14	MT